Safety of vedolizumab in the treatment of pregnant women with inflammatory bowel disease: a targeted literature review.

Birgit TerjungRenate SchmelzRobert EhehaltJochen KlausJana KnopSabine SchwindThomas WilkeAndreas Stallmach

Published in: Therapeutic advances in gastroenterology (2020)

There was no evidence for safety concerns regarding pregnancy outcomes associated with VDZ therapy. Due to the limited scope of included records, further research is needed to understand the safety profile regarding the use of VDZ during pregnancy.

Keyphrases

pregnancy outcomes
pregnant women
ulcerative colitis
case report
bone marrow
mesenchymal stem cells
drug delivery
patients with inflammatory bowel disease